Santarus Articles
Pharming and Santarus file BLA for Ruconest with US FDA
18 April 2013
Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld
6 September 2012
Santarus and Depomed expand US deal on Glumetza
23 August 2011
FDA turns down 'incomplete' Rhucin dossier
1 March 2011
Santarus gets rights to inflammatory/autoimmune disease candidate by buying Covella
15 September 2010
Pharming licenses North American rights to HAE drug Rhucin to Santarus for upfront $15 million
14 September 2010
Santarus in-licenses novel type 2 diabetes drug for US market for upfront $5 million and 35%-40% royalties
10 September 2010
Showing 1-8 of 8 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
